Skip to main content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Arch Dis Child. 2001 Mar; 84(3): 227–229.
doi: 10.1136/adc.84.3.227
PMCID: PMC1718684
PMID: 11207170

Idiopathic thrombocytopenic purpura and MMR vaccine

E Miller, P Waight, C Farrington, N Andrews, J Stowe, and B Taylor
Author information Copyright and License information Disclaimer

Abstract

A CAUSAL ASSOCIATION BETWEEN MEASLES—mumps-rubella (MMR) vaccine and idiopathic thrombocytopenic purpura (ITP) was confirmed using immunisation/hospital admission record linkage. The absolute risk within six weeks of immunisation was 1 in 22 300 doses, with two of every three cases occurring in the six week post-immunisation period being caused by MMR. Children with ITP before MMR had no vaccine associated recurrences.

Full Text

The Full Text of this article is available as a PDF (73K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  • Neiderud J. Thrombocytopenic purpura after a combined vaccine against morbilli, parotitis and rubella. Acta Paediatr Scand. 1983 Jul;72(4):613–614. [PubMed] [Google Scholar]
  • Böttiger M, Christenson B, Romanus V, Taranger J, Strandell A. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1987 Nov 14;295(6608):1264–1267. [PMC free article] [PubMed] [Google Scholar]
  • Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993 Mar;82(3):267–270. [PubMed] [Google Scholar]
  • Oski FA, Naiman JL. Effect of live measles vaccine on the platelet count. N Engl J Med. 1966 Aug 18;275(7):352–356. [PubMed] [Google Scholar]
  • Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, Rush M, Miller E. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet. 1995 Mar 4;345(8949):567–569. [PubMed] [Google Scholar]
  • Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995 Mar;51(1):228–235. [PubMed] [Google Scholar]
  • Begg NT, Gill ON, White JM. COVER (cover of vaccination evaluated rapidly): description of the England and Wales scheme. Public Health. 1989 Mar;103(2):81–89. [PubMed] [Google Scholar]
  • Cohn J. Thrombocytopenia in childhood: an evaluation of 433 patients. Scand J Haematol. 1976 Mar;16(3):226–240. [PubMed] [Google Scholar]
  • Vlacha V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics. 1996 May;97(5):738–739. [PubMed] [Google Scholar]
Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group
Feedback